Institutional Interest Surges: Seven Investment Managers Buy Abbott (ABT) Shares in Past Month

Abbott Laboratories (ticker: ABT) has seen a notable increase in institutional buying activity in recent weeks, with seven separate investment management firms purchasing shares within the past 30 days. This surge in buying comes amid sustained investor confidence in the company’s diversified healthcare portfolio and growth repositioning following its second-quarter earnings performance.

The purchases were disclosed via recent filings, marking a meaningful shift in ownership dynamics at Abbott. While the aggregate amount of shares acquired has not been disclosed, the presence of multiple institutional buyers underscores renewed confidence in ABT’s near- to mid-term prospects. 

Abbott shares are trading near $99.60 as of October 9, 2026, reflecting a modest 1.21% gain on that day in regular trading. This price comes against the backdrop of robust second-quarter results reported in mid-July, when Abbott topped earnings and revenue expectations and raised its 2026 adjusted EPS guidance to a range of $5.45 to $5.60.

During the Q2 reporting period ended June 30, 2026, Abbott posted adjusted diluted EPS of $1.31, beating consensus estimates by $0.03, and reported revenue of $12.59 billion, outperforming forecasts by approximately $90 million. The company reaffirmed its full-year comparable sales growth guidance (6.5%–7.5%) and cited strength across Nutrition, Electrophysiology, Core Laboratory, and Cancer Diagnostics as key drivers of second-half momentum.

While Abbott has benefited from these operational strengths, the recent uptick in institutional ownership suggests investors see added value in exposure to its expanding diagnostics and device segments. The ongoing integration of its Exact Sciences acquisition—completed in March 2026—continues to bolster Abbott’s position in oncology diagnostics.

The institutional activity does not appear to coincide with any newly confirmed corporate announcements or regulatory developments over the past week, suggesting the purchases reflect strategic positioning rather than reaction to discrete news events.

Looking ahead, investors may monitor further filings to assess the size and intent behind this buying trend. With institutional interest rising and a reaffirmed growth outlook, Abbott remains a key healthcare holding to watch.

Note: Abbott’s share price of $99.60 and day-over-day change of +1.21% are as of October 9, 2026, during regular trading.